Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease

Heart and Vessels

Volumn 31, Issue 10, 2016, Pages 1643-1649

  Uemura, Yusuke ^a   Shibata, Rei ^b   Takemoto, Kenji ^a   Uchikawa, Tomohiro ^a   Koyasu, Masayoshi ^a   Ishikawa, Shinji ^a   Mitsuda, Takayuki ^a   Miura, Ayako ^a   Imai, Ryo ^a   Iwamiya, Satoshi ^a   Ozaki, Yuta ^a   Kato, Tomohiro ^a   Miura, Takanori ^a   Watarai, Masato ^a   Murohara, Toyoaki ^b  

^a ANJO KOSEI HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aquaretic; Chronic kidney disease; Heart failure; Tolvaptan

Indexed keywords

CREATININE; LOOP DIURETIC AGENT; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DIURETIC THERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DEATH; HOSPITAL READMISSION; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ACUTE DISEASE; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; HEART FAILURE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; CREATININE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT READMISSION; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84948677029     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-015-0775-9     Document Type: Article

References (30)

1. Fang J, Mensah GA, Croft JB, Keenan NL (2008) Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52:428–434
2. Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, Suzuki K, Tanabe N, Kodama M, Aizawa Y (2008) Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J 72:489–491
3. Androne AS, Hryniewicz K, Hudaihed A, Mancini D, Lamanca J, Katz SD (2004) Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol 93:1254–1259
4. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B, Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei Cas L (2012) Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5:54–62
5. Kazory A, Ross EA (2008) Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation 117:975–983
6. Stevenson LW, Nohria A, Mielniczuk L (2005) Torrent or torment from the tubules? Challenge of the cardiorenal connections. J Am Coll Cardiol 45:2004–2007
7. Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS (2010) Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 160(264–271):e1
8. Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759–1764
9. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O’Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM (2004) Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147:331–338
10. Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371:1624–1632
11. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287:860–867
12. Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y (2011) Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther 25(Suppl 1):S67–S76. doi:10.1007/s10557-011-6350-4
13. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290:F273–F278
14. Matsuzaki M, Hori M, Izumi T, Fukunami M, Investigators Tolvaptan (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25(Suppl 1):S33–S45. doi:10.1007/s10557-011-6304-x
15. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O’Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA (2007) Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49:2151–2159
16. Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, Saitoh S, Kubota I, Takeishi Y, AVCMA investigators (2013) Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol 53:1277–1285
17. McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446
18. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5–S20
19. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology C (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254
20. Matsue Y, Suzuki M, Seya M, Iwatsuka R, Mizukami A, Nagahori W, Ohno M, Matsumura A, Hashimoto Y (2013) Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 61:169–174
21. Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S (2013) The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol 17:834–838
22. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 82:1724–1729
23. Nakada Y, Takahama H, Kanzaki H, Sugano T, Hasegawa T, Ohara T, Amaki M, Funada A, Yoshida A, Yasuda S, Ogawa H, Anzai T (2015) The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure. Heart Vessels. doi:10.1007/s00380-015-0688-7
24. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527–1539
25. Sarraf M, Masoumi A, Schrier RW (2009) Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 4:2013–2026
26. Takaya Y, Yoshihara F, Yokoyama H, Kanzaki H, Kitakaze M, Goto Y, Anzai T, Yasuda S, Ogawa H, Kawano Y (2014) Impact of onset time of acute kidney injury on outcomes in patients with acute decompensated heart failure. Heart Vessels. doi:10.1007/s00380-014-0572-x
27. Ueda T, Kawakami R, Sugawara Y, Okada S, Nishida T, Onoue K, Soeda T, Okayama S, Takeda Y, Watanabe M, Kawata H, Uemura S, Saito Y (2014) J Am Heart Assoc 3:e001174. doi:10.1161/JAHA.114.001174
28. Sato E, Nakamura T, Amaha M, Nomura M, Matsumura D, Yamagishi H, Ono Y, Ueda Y (2014) Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int Heart J 55:533–538
29. Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I (2014) Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 78:2240–2249
30. Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R (2013) Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients—association between non-responders and chronic kidney disease. Circ J 77:397–404